FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Dermatology Clinical Drug Pipeline Developments & Deals

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2020

            Details:

            JADE COMPARE trial met all co-primary endpoints Study included dupilumab in active control arm Safety profile for abrocitinib consistent with previous studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BX001

            Therapeutic Area: Dermatology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 20, 2020

            Details:

            BiomX is developing BX001, its lead product candidate, to modify the appearance of acne prone skin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WEG232

            Therapeutic Area: Dermatology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2020

            Details:

            WEG232 topical treatment showed a 71% reduction in SD-Rats with erlotinib-induced facial rash/hair loss.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2020

            Details:

            The recognition reinforces baricitinib's potential to be the first FDA-approved medicine for individuals living with alopecia areata.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinol

            Therapeutic Area: Dermatology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2020

            Details:

            With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASN008

            Therapeutic Area: Dermatology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2020

            Details:

            The results showed that a single application of ASN008 achieved a clinically meaningful reduction in pruritus of ? 4 points on the NRS in 2-3 hours.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Serlopitant

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Menlo Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger March 09, 2020

            Details:

            The combined company already has an approved, commercial-stage product, AMZEEQ™, and several late-stage product candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sofpironium Bromide

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 04, 2020

            Details:

            Presentation based on positive Phase 3 pivotal study results of Sofpironium Bromide in Japanese Patients with Primary Axillary Hyperhidrosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Piclidenoson

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            This year, Can-Fite's reports expand the growing data body demonstrating that both Piclidenoson and Namodenoson have beneficial safety profiles and risk-benefit ratios in over 1,500 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Roflumilast

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            Arcutis will showcase data on its investigational program studying topical roflumilast cream in patients with chronic plaque psoriasis at the 2020 American Academy of Dermatology Annual Meeting.

            PharmaCompass